Showing results (241-250 of 276) with videos related to
Sort By:
Pageof 28
Frontiers in Immunology|May 18, 2026
Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohortsClaudia Grossi, Caterina Bodio, Suresh Kumar, et al.Frontiers in Immunology|April 27, 2026
Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registryAlexander Pine, Ayesha Butt, Laura Andreoli, et al.Frontiers in Immunology|November 3, 2025
A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registryAlexander Pine, Ayesha Butt, Laura Andreoli, et al.Autoimmunity Reviews|June 10, 2018
Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?Cristina Belizna, Ljudmila Stojanovich, Jan Willem Cohen-Tervaert, et al.Annals of the Rheumatic Diseases|May 17, 2019
EULAR recommendations for the management of antiphospholipid syndrome in adultsMaria G Tektonidou, Laura Andreoli, Marteen Limper, et al.Medrxiv : the Preprint Server for Health Sciences|June 27, 2020
Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.Frontiers in Immunology|November 12, 2020
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid SyndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.Molecular Medicine (Cambridge, Mass.)|May 27, 2026
Machine learning, whole genome sequencing, and Mendelian randomization support a role of CRP on COVID-19 severityFrancesca Lantieri, Stefania Croci, Sergio Decherchi, et al.Journal of Autoimmunity|September 23, 2017
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, et al.Annals of the Rheumatic Diseases|February 6, 2021
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19Alessia Alunno, Aurélie Najm, Pedro M Machado, et al.Pageof 28